Chronic Pain Clinical Trial
Official title:
An Internet-based Multimodal Pain Program With Telephone Support for Adults With Chronic Temporomandibular Disorder Pain: Pilot Randomized Controlled Trial
Background Chronic temporomandibular disorders (TMD) pain is an undertreated condition in
Sweden despite the fact that national guidelines includes effective treatment options. These
guidelines recommend multimodal treatment with a behavioral approach. Internet-based
intervention is an appealing modality for multimodal TMD treatment, enabling more patients to
be reached and treated.
Objective To investigate the treatment effect of an internet-based multimodal pain program
(iMPP) on chronic TMD pain. As the study progressed, it also became a measure to evaluate the
feasibility of running a larger randomized controlled trial.
BACKGROUND Chronic temporomandibular disorders (TMD) pain is an undertreated condition in
Sweden despite the fact that national guidelines includes effective treatment options. These
guidelines recommend multimodal treatment with a behavioral approach. Internet-based
intervention is an appealing modality for multimodal TMD treatment, enabling more patients to
be reached and treated.
Objective To investigate the treatment effect of an internet-based multimodal pain program
(iMPP) on chronic TMD pain. As the study progressed, it also became a measure to evaluate the
feasibility of running a larger randomized controlled trial.
STUDY DESIGN An unblinded parallel-arm RCT pilot study with equal allocation was conducted.
Participants were randomized to the iMPP or to an active control. They were recruited from a
general dental care clinic (Fäladstorget) within the National Dental Care Skåne, Sweden.
Examination and allocated treatment were free of charge for participants and no other
financial compensation was given. This study is part of a large research project with the
primary objective to study changes in the brain after treatment in patients with chronic TMD
pain. Therefore, participants went through magnetic resonance imaging (MRI) of the brain pre-
and post-treatment. The study was approved by the Ethics Review Board in Lund, Sweden (No.
2016/6). This study was not registered in a public trials registry due to its feasibility
character.
PARTICIPANTS Participants had to fulfill the following criteria: (1) age between 18 and 75
years; (2) at least one of the TMD pain diagnoses myalgia, myofascial pain with referral,
headache attributed to TMD or arthralgia according to the Diagnostic Criteria for
Temporomandibular Disorders (DC/TMD) {Schiffman, 2014 #4}; (3) chronic TMD pain (≥3 months),
experienced once a week or more often, with an intensity of ≥3 on an 0-10 numeric rating
scale (NRS); (4) access to a computer with an internet connection and a mobile phone; (5)
sufficient computer literacy and (6) mastery of the Swedish language. Exclusion criteria
were: (1) chronic inflammatory systemic disease; (2) all psychiatric disorders except
depression and anxiety (due to high comorbidity); (3) occlusal splint therapy in the past 12
months; (4) ongoing extensive dental treatment; and (5) conditions contradicting MRI
examination.
Recruitment of participants started in April 2016 and ended in December 2017. Screening was
paused during holiday periods (June-August) and during February-April in 2017 due to
technical issues with the MRI machine.
PROCEDURE To identify potential participants, all consecutive adult patients visiting for a
regular dental check-up were screened. If eligible for the inclusion examination and
interested in participation oral and written information about the study was given and a new
appointment was booked. The inclusion examination was performed and written informed consent
was received. Permuted block randomization with a fixed block size of ten was used. If
allocated to iMPP, the participants received working material by mail and the URL to the
program was sent by email. Treatment start was assisted by phone. If allocated to treatment
with occlusal splint, alginate impressions and index were prepared at the same appointment as
the inclusion examination and a new appointment was booked for delivering the splint.
Follow-up was performed at three and six months after treatment start by questionnaires sent
by mail. Participants also went through an MRI of the brain at baseline (after randomization
but before treatment start) and at six months after treatment start at Skåne University
Hospital, Malmö, Sweden.
SCREENING The TMD screening tool 2Q/TMD was used to check for initial eligibility {Lövgren,
2016 #293} {Lövgren, 2016 #277}. The screening questions were (Q1) "Do you have pain in your
temple, face, jaw or jaw joint once a week or more?" and (Q2) "Do you have pain once a week
or more when you open your mouth or chew?". Participants had to answer yes to at least one of
the questions and also not fulfill any of the exclusion criteria previously mentioned to be
eligible for the inclusion examination.
INCLUSION EXAMINATION All participants underwent a standardized examination according to the
DC/TMD to control for eligibility and to collect baseline data. The DC/TMD includes a
clinical examination and questionnaires described below {Schiffman, 2014 #4}. Demographic
data and pre-treatment expectancies on allocated treatment were also assessed.
CLINICAL EXAMINATION The clinical DC/TMD examination comprises a standardized assessment of
pain and headache locations, mouth opening capacity, pain on mandibular movement, pain on
palpation, including the presence of referred pain on palpation and temporomandibular joint
noises. The clinical examinations were carried out by one of two general dentists calibrated
by the DC/TMD Training and Calibration Center at Malmö University, Sweden {Vilanova, 2015
#1}. Re-calibration of the dentists was performed mid-way through the recruitment phase.
The DC/TMD Symptom Questionnaire was used to assess pain symptoms involving the jaw, jaw
noise and locking and headache. Data from this questionnaire were combined with the findings
in the clinical examination for diagnosis according to DC/TMD {Schiffman, 2014 #4}.
QUESTIONNAIRES Pain The Graded Chronic Pain Scale was used to assess the subdomains
characteristic pain intensity (CPI; mean of pain intensity for reported worst, current and
average pain) and pain-related disability (DS; mean of how much facial pain changed the
patient's ability to participate in daily activities, social activities and work). The
questionnaire includes the assessment of pain intensity and pain-related disability that are
scored on a 0-10 NRS (modified from{Von Korff, 2011 #279}).
A full-body pain drawing was used to assess pain locations and distribution {Pain, 2020
#278}. The pain distribution was categorized as local (in face area), (iii) regional pain
(pain in the neck area in addition to local pain) and (iv) widespread pain (pain at any other
site of the body in addition to local or regional pain.
Physical functioning The Jaw Functional Limitation Scale (JLFS-8) was used to assess the
overall functional limitation of the masticatory system {Ohrbach, 2008 #280}. The Oral
Behaviors Checklist was used to assess the self-reported frequency of oral parafunctional
behaviors during awake time {Markiewicz, 2006 #281}.
Emotional functioning The Patient Health Questionnaire was used to assess depression and the
Patient Health Questionnaire-15 was used to assess non-specific physical symptoms {Kroenke,
2001 #282}{Kroenke, 2002 #283}. Anxiety was assessed with the Generalized Anxiety Disorders
Assessment-7 {Spitzer, 2006 #285}. Stress was assessed with the Perceived Stress Scale-10 and
the Pain Catastrophizing Scale was used to assess catastrophizing {Nordin, 2013
#286}{Sullivan, 1995 #287}.
Patient outcome expectancy A Swedish translation of the Stanford Expectations of Treatment
Scale (SETS) was used to assess pre-treatment expectancies on allocated treatment {Younger,
2012 #288}.
TREATMENT ARMS INTERVENTION The iMPP is based on CBT and self-management principles that help
patient cope with chronic TMD pain. It was developed by orofacial pain specialists at the
Department of Orofacial Pain and Jaw Function, Malmö University, Sweden, in collaboration
with Psykologpartners AB (a Swedish supplier of internet-based psychological treatment).
The iMPP translates a face-to-face therapy to a software platform program. It can be reached
through an URL wherever an internet connection is available and access requires a 2-factor
authentication system. A paper-back workbook with homework assignments is included in
addition to the internet program. The iMPP consists of seven treatment modules; each
described in Table 1 and print screens of the program is shown in Figure 1. Recurrent in each
module was a rating of pain frequency, stress levels and life satisfaction to keep track of
progression (Fig. 1). Seven weeks was the intended treatment duration: 1 module/week; 40
min/module online plus time for homework assignments. However, access to the program was not
time-limited in this pilot study.
The iMPP was designed to be used without HCP involvement, however, in this study, guidance
was included in order to increase adherence. A dentist (JL) provided a start-up phone call,
follow-up phone calls after each finished module and also sent reminders if necessary. The
dentist was also available for additional support through the chat function in the program
(asynchronous). At the start-up phone call, participants were guided through the functions in
the program and informed about time requirements for the treatment. Follow-up phone calls
involved individualized support and feedback; and if participants were unreachable at
scheduled follow-up calls, a message through the chat function was sent with the prompt to
get in touch. The dentist who guided the treatment had received a 2-day training on
internet-based CBT treatment arranged by Psykologpartners AB.
CONTROL CONDITION Participants randomized to active control received a hard Michigan-type
stabilization splint placed in the upper jaw by one of two calibrated general dentists
{Ramfjord, 1994 #276}. The splints were made of acrylic, covered all the maxillary teeth and
had a smooth flat surface. Within 2-6 weeks after treatment start, a check-up appointment was
booked. At this check-up appointment, the splint was controlled and, if needed, adjusted.
Participants were also encouraged to continue using it.
FOLLOW-UP Follow-up was performed with questionnaires comprising a short version of the
DC/TMD axis II instruments.
OUTCOME MEASURES PRELIMINARY EVALUATION OF PARTICIPANT RESPONSES TO INTERVENTION Measures
specific to TMD included in the DC/TMD were used as outcome measures, as guided by the
Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT). Primary
outcomes included characteristic pain intensity, pain-related disability and physical
functioning (CPI, DS and JFLS-8). Secondary outcomes were depression and anxiety as measures
of emotional functioning. In addition to the IMMPACT core domains, catastrophizing and stress
were evaluated as secondary outcomes.
FEASIBILITY Evaluation of the feasibility of the study concerned testing the study protocol
and estimation of recruitment and attrition rates in the current research setting. With
preliminary results, a post hoc power and sample size calculation were performed. With
knowledge of recruitment and attrition rate together with a new estimated sample size, a
decision of the feasibility of performing future larger RCT could be taken. The usage metrics
of iMPP were not assessed.
ADVERSE EFFECTS Adverse events for iMPP treatment were collected through the follow-up phone
calls. Also, all participants randomized to iMPP were given written information at the
3-month follow-up about the opportunity to withdraw from the study and receive rescue
treatment if symptoms worsened or they were not satisfied with treatment outcome.
STATISTICAL ANALYSIS Non-parametric statistics were used due to the characteristics of the
pain-related variables. Post-hoc power analysis with CPI as the outcome measure was
performed. The sample size required for a parametric test on between-group comparison was
computed and then 15% additional subjects were added since non-parametric testing will be
used in a future RCT {GraphPad Software, 2020 #289}.
Estimation of required sample size was based on a previous neuroimaging study to detect
statistically significant results in functional MRI {Gracely, 2002 #290}. According to this,
20 participants in each group should be recruited.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|